1,500,000 Shares Repligen Corporation UNDERWRITING AGREEMENTRepligen Corp • December 8th, 2020 • Biological products, (no disgnostic substances) • New York
Repligen Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A hereto (the “Underwriters”) an aggregate of 1,500,000 shares of its common stock, par value $0.01 per share (the “Common Stock”). The 1,500,000 shares of Common Stock to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 225,000 shares of Common Stock as provided in Section 2. The additional 225,000 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” J.P. Morgan Securities LLC (“J.P. Morgan”) and Stifel, Nicolaus & Company, Incorporated have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connecti
